The online version of this article (doi:10.1007/s00403-017-1736-1) contains supplementary material, which is available to authorized users.
Bullous pemphigoid (BP) is a chronic debilitating autoimmune blistering disease that frequently occurs in the elderly population. Previous studies have suggested a high morbidity and mortality associated with BP. However, relatively few studies have investigated prognostic factors of BP mortality, and they showed considerably various results. This meta-analysis aimed to quantitatively assess the association between several potential prognostic factors and risk of mortality in bullous pemphigoid. A comprehensive search was performed using Pubmed, Embase, and Cochrane Library. Cohort studies that assessed prognostic factors of BP mortality were included. Random-effects model was utilized to calculate the pooled hazard ratio (HR). Publication bias was evaluated qualitatively by constructing a funnel plot and quantitatively by conducting Egger’s test. 14 studies were included comprising 2499 patients. Combined HRs suggested that advanced age (HR 1.63, 95% CI 1.34–1.97), presence of circulating antibodies (HR 1.77, 95% CI 1.20–2.62), concomitant dementia (HR 2.01, 95% CI 1.22–3.33), and concomitant stroke (HR 1.86, 95% CI 1.29–2.67) have an unfavorable impact on patient survival. Gender, disease extent, mucosal involvement, and indirect immunofluorescence result were not shown to be linked to mortality by our analysis. This study indicated that BP patients with older age, circulating antibodies, dementia, and stroke are at greater risk of mortality. Clinicians should be aware of this association and utilize this information in patient education and treatment process.
Desai BS, Monahan AJ, Carvey PM, Hendey B (2007) Blood-brain barrier pathology in Alzheimer’s and Parkinson’s disease: implications for drug therapy. Cell Transpl 16:285–299 CrossRef
Fichel F, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Michel C, Jegou J, Grange F, Antonicelli F, Bernard P (2014) Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol 150:25–33 CrossRefPubMed
Försti AK, Jokelainen J, Timonen M, Tasanen K (2016) Risk of death in bullous pemphigoid: a retrospective database study in Finland. Acta Derm Venereol 96:758–761 PubMed
McPheeters ML, Kripalani S, Peterson NB, Idowu RT, Jerome RN, Potter SA, Andrews JC (2012) Closing the quality gap: revisiting the state of the science (vol. 3: quality improvement interventions to address health disparities). Evid Rep Technol Assess (Full Rep) 208.3:1–475
Ren Z, Hsu DY, Brieva J, Silverberg NB, Langan SM, Silverberg JI (2016) Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. Br J Dermatol. doi: 10.1111/bjd.14821
Zhang LM, Wu J, Xiao T, Jin GY, Li JH, Geng L, He CD, Gao XH, Chen HD (2013) Treatment and mortality rate of bullous pemphigoid in China: a hospital-based study. Eur J Dermatol 23:94–98 PubMed
- Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis
- Springer Berlin Heidelberg
Neu im Fachgebiet Dermatologie
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II